NYSE:MCK

McKesson Competitors

$191.58
+0.71 (+0.37 %)
(As of 04/12/2021 04:00 PM ET)
Add
Compare
Today's Range
$189.36
Now: $191.58
$193.07
50-Day Range
$169.52
MA: $184.54
$196.53
52-Week Range
$125.65
Now: $191.58
$198.43
Volume37,966 shs
Average Volume1.03 million shs
Market Capitalization$30.49 billion
P/E Ratio14.58
Dividend Yield0.88%
Beta0.94

Competitors

McKesson (NYSE:MCK) Vs. GSK, SYK, ISRG, ANTM, GILD, and ZTS

Should you be buying MCK stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to McKesson, including GlaxoSmithKline (GSK), Stryker (SYK), Intuitive Surgical (ISRG), Anthem (ANTM), Gilead Sciences (GILD), and Zoetis (ZTS).

GlaxoSmithKline (NYSE:GSK) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Dividends

GlaxoSmithKline pays an annual dividend of $2.52 per share and has a dividend yield of 7.0%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. GlaxoSmithKline pays out 79.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. McKesson pays out 11.2% of its earnings in the form of a dividend. GlaxoSmithKline has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years.

Risk & Volatility

GlaxoSmithKline has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for GlaxoSmithKline and McKesson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GlaxoSmithKline34602.23
McKesson021012.92

McKesson has a consensus target price of $196.00, suggesting a potential upside of 2.18%. Given McKesson's stronger consensus rating and higher possible upside, analysts clearly believe McKesson is more favorable than GlaxoSmithKline.

Valuation and Earnings

This table compares GlaxoSmithKline and McKesson's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlaxoSmithKline$43.10 billion2.25$5.93 billion$3.1711.38
McKesson$231.05 billion0.13$900 million$14.9512.81

GlaxoSmithKline has higher earnings, but lower revenue than McKesson. GlaxoSmithKline is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

11.8% of GlaxoSmithKline shares are held by institutional investors. Comparatively, 85.6% of McKesson shares are held by institutional investors. 10.0% of GlaxoSmithKline shares are held by company insiders. Comparatively, 0.3% of McKesson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares GlaxoSmithKline and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GlaxoSmithKline18.50%29.60%7.11%
McKesson0.95%45.52%4.42%

Summary

McKesson beats GlaxoSmithKline on 12 of the 18 factors compared between the two stocks.

Stryker (NYSE:SYK) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Analyst Recommendations

This is a summary of current recommendations for Stryker and McKesson, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker161412.68
McKesson021012.92

Stryker currently has a consensus price target of $234.6818, indicating a potential downside of 6.81%. McKesson has a consensus price target of $196.00, indicating a potential upside of 2.18%. Given McKesson's stronger consensus rating and higher possible upside, analysts plainly believe McKesson is more favorable than Stryker.

Valuation and Earnings

This table compares Stryker and McKesson's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion6.36$2.08 billion$8.2630.48
McKesson$231.05 billion0.13$900 million$14.9512.81

Stryker has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker12.35%20.94%8.77%
McKesson0.95%45.52%4.42%

Dividends

Stryker pays an annual dividend of $2.52 per share and has a dividend yield of 1.0%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Stryker pays out 30.5% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years and McKesson has increased its dividend for 4 consecutive years.

Volatility & Risk

Stryker has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

Institutional and Insider Ownership

71.5% of Stryker shares are owned by institutional investors. Comparatively, 85.6% of McKesson shares are owned by institutional investors. 6.8% of Stryker shares are owned by company insiders. Comparatively, 0.3% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

McKesson beats Stryker on 9 of the 17 factors compared between the two stocks.

McKesson (NYSE:MCK) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Earnings and Valuation

This table compares McKesson and Intuitive Surgical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
McKesson$231.05 billion0.13$900 million$14.9512.81
Intuitive Surgical$4.48 billion20.60$1.38 billion$9.9578.34

Intuitive Surgical has lower revenue, but higher earnings than McKesson. McKesson is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

McKesson has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Insider & Institutional Ownership

85.6% of McKesson shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 0.3% of McKesson shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for McKesson and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
McKesson021012.92
Intuitive Surgical381102.36

McKesson currently has a consensus price target of $196.00, suggesting a potential upside of 2.18%. Intuitive Surgical has a consensus price target of $750.9444, suggesting a potential downside of 3.62%. Given McKesson's stronger consensus rating and higher probable upside, analysts clearly believe McKesson is more favorable than Intuitive Surgical.

Profitability

This table compares McKesson and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
McKesson0.95%45.52%4.42%
Intuitive Surgical24.45%12.08%10.44%

Summary

Intuitive Surgical beats McKesson on 9 of the 15 factors compared between the two stocks.

Anthem (NYSE:ANTM) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Dividends

Anthem pays an annual dividend of $4.52 per share and has a dividend yield of 1.3%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Anthem pays out 23.3% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years.

Risk & Volatility

Anthem has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, McKesson has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Anthem and McKesson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthem031602.84
McKesson021012.92

Anthem currently has a consensus target price of $358.85, suggesting a potential downside of 0.24%. McKesson has a consensus target price of $196.00, suggesting a potential upside of 2.18%. Given McKesson's stronger consensus rating and higher possible upside, analysts clearly believe McKesson is more favorable than Anthem.

Institutional & Insider Ownership

89.4% of Anthem shares are held by institutional investors. Comparatively, 85.6% of McKesson shares are held by institutional investors. 0.2% of Anthem shares are held by insiders. Comparatively, 0.3% of McKesson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Anthem and McKesson's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthem$104.21 billion0.84$4.81 billion$19.4418.48
McKesson$231.05 billion0.13$900 million$14.9512.81

Anthem has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anthem and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthem4.22%18.45%7.27%
McKesson0.95%45.52%4.42%

Summary

Anthem beats McKesson on 10 of the 18 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Risk & Volatility

Gilead Sciences has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
McKesson0.95%45.52%4.42%

Analyst Ratings

This is a summary of current ratings for Gilead Sciences and McKesson, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191402.54
McKesson021012.92

Gilead Sciences currently has a consensus price target of $97.2308, indicating a potential upside of 50.26%. McKesson has a consensus price target of $196.00, indicating a potential upside of 2.18%. Given Gilead Sciences' higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than McKesson.

Valuation and Earnings

This table compares Gilead Sciences and McKesson's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.63$5.39 billion$6.1410.53
McKesson$231.05 billion0.13$900 million$14.9512.81

Gilead Sciences has higher earnings, but lower revenue than McKesson. Gilead Sciences is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 85.6% of McKesson shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 0.3% of McKesson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dividends

Gilead Sciences pays an annual dividend of $2.84 per share and has a dividend yield of 4.4%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Gilead Sciences pays out 46.3% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years.

Summary

McKesson beats Gilead Sciences on 10 of the 18 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. McKesson pays an annual dividend of $1.68 per share and has a dividend yield of 0.9%. Zoetis pays out 27.5% of its earnings in the form of a dividend. McKesson pays out 11.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and McKesson has raised its dividend for 4 consecutive years. McKesson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

92.5% of Zoetis shares are owned by institutional investors. Comparatively, 85.6% of McKesson shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.3% of McKesson shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zoetis and McKesson, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06902.60
McKesson021012.92

Zoetis currently has a consensus target price of $170.0833, suggesting a potential upside of 4.50%. McKesson has a consensus target price of $196.00, suggesting a potential upside of 2.18%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than McKesson.

Profitability

This table compares Zoetis and McKesson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
McKesson0.95%45.52%4.42%

Earnings and Valuation

This table compares Zoetis and McKesson's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion12.33$1.50 billion$3.6444.63
McKesson$231.05 billion0.13$900 million$14.9512.81

Zoetis has higher earnings, but lower revenue than McKesson. McKesson is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Zoetis has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Summary

McKesson beats Zoetis on 10 of the 18 factors compared between the two stocks.


McKesson Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$36.07+1.6%$98.68 billion$43.10 billion11.10
Stryker logo
SYK
Stryker
2.0$251.74+0.6%$95.33 billion$14.88 billion54.61Insider Selling
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$779.45+0.6%$92.87 billion$4.48 billion88.78
Anthem logo
ANTM
Anthem
2.4$359.21+0.5%$88.41 billion$104.21 billion18.57
Gilead Sciences logo
GILD
Gilead Sciences
2.8$64.64+0.7%$81.98 billion$22.45 billion66.64
Zoetis logo
ZTS
Zoetis
2.2$162.46+1.6%$75.93 billion$6.26 billion48.21
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.2$247.21+0.3%$72.04 billion$17.12 billion90.55
HCA Healthcare logo
HCA
HCA Healthcare
2.3$191.65+0.4%$64.31 billion$51.34 billion19.38Analyst Report
Illumina logo
ILMN
Illumina
1.6$399.01+1.1%$58.85 billion$3.54 billion92.58
Moderna logo
MRNA
Moderna
1.6$139.35+1.1%$56.44 billion$60.21 million-86.02Insider Selling
Gap Down
Boston Scientific logo
BSX
Boston Scientific
2.0$39.34+0.1%$55.85 billion$10.74 billion15.07News Coverage
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.71+0.2%$55.46 billion$4.16 billion26.98Analyst Report
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.3$17.14+0.6%$54.38 billion$30.20 billion57.14
Humana logo
HUM
Humana
2.3$413.29+1.1%$53.89 billion$64.89 billion13.25
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.4$85.80+0.2%$53.49 billion$4.35 billion68.64Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$473.09+0.4%$50.91 billion$7.86 billion17.29News Coverage
Align Technology logo
ALGN
Align Technology
1.9$601.50+1.5%$46.89 billion$2.41 billion27.37
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$506.82+0.8%$43.06 billion$2.41 billion88.30
Baxter International logo
BAX
Baxter International
1.9$84.53+0.5%$42.89 billion$11.36 billion48.03
Biogen logo
BIIB
Biogen
1.9$262.94+2.0%$40.85 billion$14.38 billion8.70Analyst Report
DexCom logo
DXCM
DexCom
1.9$387.13+1.1%$36.83 billion$1.48 billion159.97
Centene logo
CNC
Centene
2.1$62.43+0.3%$36.41 billion$74.64 billion17.39
Alcon logo
ALC
Alcon
1.5$73.69+0.1%$36.00 billion$7.51 billion-50.13
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$168.49+0.6%$35.31 billion$7.98 billion1,053.13Analyst Upgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$154.05+0.6%$34.08 billion$4.99 billion35.99
BioNTech logo
BNTX
BioNTech
0.9$121.51+0.5%$29.41 billion$121.63 million-60.76Analyst Revision
ResMed logo
RMD
ResMed
1.5$201.86+1.3%$28.98 billion$2.96 billion43.32
BeiGene logo
BGNE
BeiGene
1.3$294.39+4.7%$28.23 billion$428.21 million-14.57
Teladoc Health logo
TDOC
Teladoc Health
1.7$182.00+0.4%$27.68 billion$553.31 million-127.27Analyst Revision
Seagen logo
SGEN
Seagen
1.7$140.68+1.5%$25.90 billion$916.71 million55.39Insider Selling
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.2$255.50+0.3%$24.87 billion$11.55 billion29.74
AmerisourceBergen logo
ABC
AmerisourceBergen
1.7$117.59+0.7%$23.91 billion$189.89 billion-7.00
Genmab A/S logo
GMAB
Genmab A/S
1.6$33.60+1.7%$22.42 billion$804.57 million26.05
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$38.17+1.5%$22.02 billion$19.58 billion15.15
Cerner logo
CERN
Cerner
2.6$73.56+1.0%$22.00 billion$5.69 billion28.73Unusual Options Activity
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$296.72+0.1%$21.90 billion$1.84 billion78.29
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.04+0.4%$21.23 billion$876.29 million-56.58
10x Genomics logo
TXG
10x Genomics
1.6$188.36+3.3%$21.17 billion$245.89 million-139.52
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$89.84+1.8%$20.50 billion$1.30 billion24.55
Teleflex logo
TFX
Teleflex
1.8$426.29+0.2%$19.97 billion$2.60 billion54.86
The Cooper Companies logo
COO
The Cooper Companies
1.9$387.95+0.5%$18.97 billion$2.43 billion80.66
Insulet logo
PODD
Insulet
1.4$284.85+0.8%$18.97 billion$738.20 million647.40
Hologic logo
HOLX
Hologic
1.9$74.40+1.0%$18.97 billion$3.78 billion17.71
Catalent logo
CTLT
Catalent
1.7$109.43+0.2%$18.60 billion$3.09 billion69.70
Avantor logo
AVTR
Avantor
1.8$32.99+3.8%$18.24 billion$6.04 billion274.92News Coverage
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$603.95+0.2%$17.98 billion$2.31 billion5.17
Cardinal Health logo
CAH
Cardinal Health
2.4$60.83+1.3%$17.63 billion$152.92 billion18.38
Incyte logo
INCY
Incyte
1.9$79.88+0.1%$17.58 billion$2.16 billion-50.88
BIO.B
Bio-Rad Laboratories
0.7$579.38+0.0%$17.28 billion$2.31 billion4.96
STERIS logo
STE
STERIS
2.1$200.67+0.8%$17.00 billion$3.03 billion40.70
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.